{"analyses":[{"ciLowerLimit":"0.412","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.783","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0005","pValueComment":"Two-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.57","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.6","upperLimit":"21.9","value":"19.1"},{"groupId":"OG001","lowerLimit":"6.9","upperLimit":"12.2","value":"8.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"description":"The TFST was defined as the time from the date of randomization to the start date of the first subsequent anti-cancer therapy or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.","id":"OG000","title":"gBRCA Niraparib"},{"description":"Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.","id":"OG001","title":"gBRCA Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From date of randomization to the earliest date of first subsequent therapy or death, up to 7 years, 7 months and 4 days","title":"Time to First Subsequent Therapy in Cohort With Germline BRCA Mutation (gBRCA)","type":"SECONDARY","unitOfMeasure":"Months"}